Valuation: Solara Active Pharma Sciences Limited

Market Cap 30.52B 321M 288M 265M 240M 449M 457M 3.16B 1.27B 16.06B 1.21B 1.18B 50.63B P/E 2025
3,792x
P/E 2026 -253x
Enterprise Value 37.31B 393M 352M 324M 293M 548M 559M 3.86B 1.55B 19.63B 1.47B 1.44B 61.9B EV / Sales 2025
2.54x
EV / Sales 2026 1.99x
Free-Float
47.77%
Yield 2025 *
-
Yield 2026 -
1 day-3.46%
1 week+3.44%
Current month-12.79%
1 month-12.79%
3 months+24.53%
6 months+27.59%
Current year+11.97%
1 week 604.95
Extreme 604.95
669
1 month 525.15
Extreme 525.15
759
Current year 422
Extreme 422
774
1 year 422
Extreme 422
774
3 years 286
Extreme 286
882.8
5 years 286
Extreme 286
1,384
10 years 134.5
Extreme 134.5
1,859.95
Manager TitleAgeSince
Chief Executive Officer - 21/02/2025
Director of Finance/CFO - 21/02/2025
Chief Tech/Sci/R&D Officer 74 10/08/2026
Director TitleAgeSince
Chairman 73 11/04/2018
Director/Board Member 58 11/04/2018
Director/Board Member 75 14/11/2023
Date Insider Type Main position Quantity % Market Cap. Importance
3/14/25 A Buy

Director

1,000 0.0021%
3/6/25 A
Pronomz Ventures LLP
BuyCompany 13,600 0.0283%
3/4/25 A
Pronomz Ventures LLP
BuyCompany 216,361 0.4503%
Change 5-day change 1-year change 3-year change Capi.($)
-3.46%+3.44% - - 321M
Average -3.46%
Weighted average by Cap. -3.46%

Financials

2025 2026
Net sales 12.84B 135M 121M 111M 101M 189M 192M 1.33B 533M 6.75B 507M 497M 21.3B 13.69B 144M 129M 119M 108M 201M 205M 1.42B 569M 7.2B 541M 530M 22.71B
Net income 5.4M 56.87K 50.93K 46.85K 42.45K 79.35K 80.84K 559K 224K 2.84M 213K 209K 8.96M -74.1M -780K -699K -643K -583K -1.09M -1.11M -7.67M -3.08M -38.98M -2.93M -2.87M -123M
Net Debt 7.92B 83.43M 74.72M 68.73M 62.27M 116M 119M 820M 329M 4.17B 313M 306M 13.14B 6.79B 71.52M 64.05M 58.92M 53.38M 99.79M 102M 703M 282M 3.57B 268M 263M 11.27B
Projected Income Statement - Annual - Solara Active Pharma Sciences Limited
Logo Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.
Employees
1,669
Date Price Change Volume
30/10/26 ₹632.60 -3.46% 145,352
29/10/26 ₹655.25 +0.22% 108,382
28/10/26 ₹653.80 +2.69% 218,304
27/10/26 ₹636.70 +0.34% 314,775
26/10/26 ₹634.55 +3.76% 242,609

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Solara Active Pharma Sciences Limited
  1. Stock Market
  2. Stocks
  3. SOLARA Stock